Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Endometrial Neoplasms 3Breast Neoplasms 3Sarcoma 2Prostatic Neoplasms 2Neoplasms 2Recurrence 1Primary Myelofibrosis 1Osteosarcoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancers 1

Interventions

Docetaxel 137Prednisone 120Abiraterone Acetate 91Leuprolide 86enzalutamide 84Radiotherapy 59bicalutamide 56Magnetic Resonance Spectroscopy 54Goserelin 54Androgen Antagonists 51acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47apalutamide 44abiraterone 34Radiosurgery 31Specimen Handling 30gallium 68 PSMA-11 29Gonadotropin-Releasing Hormone 29cabazitaxel 28Carboplatin 27darolutamide 26Estramustine 24luprolide acetate gel depot 23relugolix 22Metformin 22Triptorelin Pamoate 20sipuleucel-T 19radium Ra 223 dichloride 19Radiation 19pembrolizumab 18deltacortene 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms × ridaforolimus × Clear all
NCT00110188 2015-11-20

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Merck Sharp & Dohme LLC

Phase 2 Completed
39 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00777959 2015-08-19

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)

Merck Sharp & Dohme LLC

Phase 2 Completed
22 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡